Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;40(2):501-517.
doi: 10.1007/s10555-021-09964-4. Epub 2021 Apr 15.

MHC heterogeneity and response of metastases to immunotherapy

Ignacio Algarra  1 , Federico Garrido  2   3   4 , Angel M Garcia-Lora  5   6   7
Affiliations
Review

MHC heterogeneity and response of metastases to immunotherapy

Ignacio Algarra et al. Cancer Metastasis Rev. 2021 Jun.

Abstract

In recent years, immunotherapy has proven to be an effective treatment against cancer. Cytotoxic T lymphocytes perform an important role in this anti-tumor immune response, recognizing cancer cells as foreign, through the presentation of tumor antigens by MHC class I molecules. However, tumors and metastases develop escape mechanisms for evading this immunosurveillance and may lose the expression of these polymorphic molecules to become invisible to cytotoxic T lymphocytes. In other situations, they may maintain MHC class I expression and promote immunosuppression of cytotoxic T lymphocytes. Therefore, the analysis of the expression of MHC class I molecules in tumors and metastases is important to elucidate these escape mechanisms. Moreover, it is necessary to determine the molecular mechanisms involved in these alterations to reverse them and recover the expression of MHC class I molecules on tumor cells. This review discusses the role and regulation of MHC class I expression in tumor progression. We focus on altered MHC class I phenotypes present in tumors and metastases, as well as the molecular mechanisms responsible for MHC-I alterations, emphasizing the mechanisms of recovery of the MHC class I molecules expression on cancer cells. The individualized study of the HLA class I phenotype of the tumor and the metastases of each patient will allow choosing the most appropriate immunotherapy treatment based on a personalized medicine.

Keywords: Antitumor immunity; Heterogeneity; Immunotherapy; MHC; MHC-I restoration; Metastases.

PubMed Disclaimer

References

    1. Gorer, P. A. (1936). The detection of antigenic differences in mouse erythrocytes by the employment of immune Sera. British Journal of Experimental Pathology, 17(1), 42–50 Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2065193/ . - PMC
    1. Dausset, J. (1952). The agglutination mechanism of trypsin modified red cells. Blood, 7(8), 816–825. https://doi.org/10.1182/blood.V7.8.816.816 . - DOI - PubMed
    1. Bjorkman, P. J., & Parham, P. (1990). Structure, function, and diversity of class I major histocompatibility complex molecules. Annual Review of Biochemistry, 59, 253–288. https://doi.org/10.1146/annurev.bi.59.070190.001345 . - DOI - PubMed
    1. Le Bouteiller, P. (2017). HLA Class I chromosomal region, genes, and products: Facts and questions. Critical Reviews in Immunology, 37(2–6), 317–357. https://doi.org/10.1615/CritRevImmunol.v37.i2-6.80 . - DOI - PubMed
    1. Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013). MHC class I antigen processing and presenting machinery: Organization, function, and defects in tumor cells. Journal of the National Cancer Institute, 105(16), 1172–1187. https://doi.org/10.1093/jnci/djt184 . - DOI - PubMed

Publication types

Substances